EE462 Cost-Effectiveness of Nivolumab for the Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma Patients With High Risk of Recurrence and Tumor Cell Pd-L1 Expression ≥ 1% in Sweden
| Autor: | Kamgar, F, Johannesen, K, Thybo, SH, Teitsson, S, Brodtkorb, TH |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S146-S146 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect